Cost analysis of living donor kidney transplantation in China: A single-center experience

Annals of Transplantation

Volumn 17, Issue 2, 2012, Pages 5-10

  Zhao, Wenyu ^a   Zhang, Lei ^a   Han, Shu ^a   Zhu, Youhua ^a   Wang, Liming ^a   Zhou, Meisheng ^a   Zeng, Li ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Financial analysis; Hospital cost; Living donor kidney transplantation

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BODY WEIGHT; CHINA; DRUG COST; FEMALE; GRAFT RECIPIENT; GROUPS BY AGE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LIVING DONOR; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NURSING CARE; POSTOPERATIVE INFECTION;

EID: 84863557407     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.883217     Document Type: Article

References (13)

1. Niakas D, Kontodimopoulos N: Is renal transplantation the most cost-effective and preferable therapy for patients suffering from endstage renal disease or not? Health Policy, 2009; 89: 329-31
2. Wolfe RA, Ashby VB, Milford EL et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med, 1999; 341: 1725-30
3. Evans RW, Kitzmann DJ: An economic analysis of kidney transplantation. Surg Clin North Am, 1998; 78: 149-74
4. Nourbala MH, Einollahi B, Kardavani B et al: The cost of kidney transplantation in Iran. Transplant Proc, 2007; 39: 927-29
5. Elsharif ME, Elsharif EG, Gadour WH: Costs of hemodialysis and kidney transplantation in Sudan: a single center experience. Iran J Kidney Dis, 2010; 4: 282-84
6. Hagenmeyer EG, Häussler B, Hempel E et al: Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications. Transplantation, 2004; 77: 1545-50
7. Chaumard N, Fagnoni P, Nerich V et al: Hospital costs of renal transplant management. Transplant Proc, 2008; 40: 3440-44
8. Saidi RF, Elias N, Kawai T et al: Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant, 2007; 7: 2769-74
9. Gaber AO, Knight RJ, Patel S et al: A Review of the Evidence for Use of Thymoglobulin Induction in Renal Transplantation. Transplant Proc, 2010; 42: 1395-400
10. Hardinger KL, Rasu RS, Skelton R et al: Thymoglobulin induction dosing strategies in a lowrisk kidney transplant population: three or four days? J Transplant, 2010; 2010: 957549
11. Schenker P, Ozturk A, Vonend O et al: Singledose thymoglobulin induction in living-donor renal transplantation. Ann Transplant, 2011; 16: 50-58
12. Patton PR, Brunson ME, Pfaff WW et al: A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation, 1994; 57: 889-92
13. Gerntholtz T, Pascoe MD, Botha JF et al: The use of a cyclosporin-ketoconazole combination: Making renal transplantation affordable in developing countries. Eur J Clin Pharmacol, 2004; 60: 143-48